At a glance
- Originator Sanofi Winthrop
- Class Anti-ischaemics
- Mechanism of Action Glutamate receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cognition disorders
Most Recent Events
- 23 Sep 1996 Discontinued-Preclinical for Cognition disorders in USA (Unknown route)
- 29 Aug 1996 New profile
- 29 Aug 1996 Preclinical development for Cognition disorders in USA (Unknown route)